Evidence map›Paper›PMID 40028580›Full record

ArticleHeliyon2025

Network pharmacology and molecular analysis of mechanisms underlying the therapeutic effects of Rhubarb in treating atherosclerosis and abdominal aortic aneurysm.

Huilin Xu, Jun Huang, Youjie Zeng, Xia Wang, Huilin Lian, Siyi Zhang, Ren Guo

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huilin XuDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Jun HuangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Youjie ZengDepartment of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xia WangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Huilin LianDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Siyi ZhangDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Ren GuoDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim of the study: The aim of this study was to systematically investigate the effects and mechanisms of Rhubarb in the treatment of Atherosclerosis (AS) and Abdominal Aortic Aneurysm (AAA) by utilizing network pharmacology and molecular docking techniques. Materials and methods: TCMSP systematic pharmacology database was utilized to search for active chemical components of Rhubarb. Disease-related targets were retrieved from the GEO dataset and Disgenet database. Gene interactions were utilized to identify common targets of Rhubarb with AS/AAA, and interaction networks were constructed using Cytoscape 3.9.1. Protein-protein interaction (PPI) networks for the core targets were constructed using the STRING database. GO and KEGG pathway enrichment analysis was performed using DAVID. Molecular docking is used to assess the potential target-active compound interactions. Results: In our study, 16 active compounds were screened from Rhubarb Conclusions: This study successfully predicted the molecular functions, pharmacological targets, and pathways associated with Rhubarb for treating AS/AAA. In addition, identified potential active ingredients can be used as a source for AS/AAA drug screening.

Indexed as

Abdominal aortic aneurysmAtherosclerosisComputational biologyCyberpharmacologyMolecular docking technologyRhubarbTraditional Chinese medicine

Identifiers

PMID40028580
PMCPMC11867279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.